Keywords: Chronic lymphocytic leukemia; Small lymphocytic lymphoma; CLL; Melanoma; Immune checkpoint inhibitors; Pembrolizumab; PD-1 inhibitor;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Genomic profiling; Immunotherapy; PD-1 inhibitor; Small-cell carcinoma of the bladder; Variant histology;
Keywords: Treatment beyond progression; Non-small cell lung carcinoma; PD-1 inhibitor; Immunotherapy;
Keywords: Programmed cell death 1; PD-1; PDCD1; anti-PD-1 antibody; PD-1 inhibitor; nivolumab; pembrolizumab; acute interstitial nephritis (AIN); acute kidney injury (AKI); non-small cell lung cancer (NSCLC); advanced melanoma; ipilimumab; immune checkpoint inhib
CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC
Keywords: Lung neoplasm; Immunotherapy; Pseudoprogression; PD-1 inhibitor; CD103;
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer
Keywords: Checkpoint inhibitor; Immunotherapy; Lung cancer; NLR; PD-1 inhibitor;
The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis
Keywords: Immune-related endocrine disorders; PD-1 inhibitor; Meta-analysis;
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer
Keywords: NSCLC; Radiation; Immunotherapy; PD-1 inhibitor; Brain metastases;
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
Keywords: Non-small cell lung cancer; PD-1 inhibitor; Nivolumab; Crizotinib; anaplastic lymphoma kinase translocation;
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Keywords: Advanced renal cell carcinoma; Immune checkpoint inhibitor; Immunotherapy agents; Nivolumab; Second-line therapy; PD-1 inhibitor;
PD-1 checkpoint inhibition: Toxicities and management
Keywords: Immune-related adverse events; PD-1 inhibitor; PD-L1 inhibitor; Treatment; Management; Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab;
Original ResearchProgrammed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Keywords: Metastatic melanoma; Nivolumab; Pembrolizumab; PD-1 inhibitor; Autoimmunity; Ipilimumab; Immune-related adverse events;
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Keywords: Bladder cancer; PD-L1 inhibitor; PD-1 inhibitor; BCG; Immunotherapy;
Unresectable Cutaneous Squamous Cell Carcinoma of the Forehead With MLH1 Mutation Showing Dramatic Response to Programmed Cell Death Protein 1 Inhibitor Therapy
Keywords: Cutaneous SCC; DNA mismatch repair; Immunotherapy; PD-1 inhibitor; Unresectable cutaneous cancer;